Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobinostat in Pediatric Solid Tumors (NORTH)
NCT04897880Phase 2Terminated
- Sponsor
- Australia & New Zealand Children’s Haematology and Oncology Group
- Start
- Jan 2019
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of panobinostat in osteosarcoma (OS), malignant rhabdoid tumor (MRT), Atypical teratoid rhabdoid tumor (ATRT), neuroblastoma, sponsored by Australia & New Zealand Children’s Haematology and Oncology Group. Started Jan 2019; status: terminated.
02
Drugs
panobinostat
03
Conditions
osteosarcoma (OS)malignant rhabdoid tumor (MRT)Atypical teratoid rhabdoid tumor (ATRT)neuroblastoma
Beyond the preview
Go deeper on NCT04897880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04897880.